Breaking News

Antares Earns Second OTREXUP Milestone

By Kristin Brooks | March 12, 2014

LEO Pharma launches psoriasis drug

Antares Pharma, Inc. has received a second $5 million milestone payment from LEO Pharma in connection with the launch of OTREXUP. In November 2013, the companies entered an exclusive license and promotion agreement for OTREXUP (methotrexate) for symptomatic control of severe recalcitrant psoriasis in adults, under which Antares is eligible to receive as much as $20 million in milestone payments. LEO Pharma is responsible for all promotion and marketing costs in dermatology. 
 
“We are excited that our partnership with LEO Pharma continues to evolve quickly,” said Paul Wotton, Ph.D., president and chief executive officer of Antares Pharma. “In just four short months since the approval of OTREXUP, our collaboration has achieved a second significant milestone while still very early in the rheumatoid arthritis launch phase. We look forward to a successful launch of OTREXUP for the psoriasis indication, and the expertise LEO’s dedicated U.S. sales force of 75 representatives will bring to the overall commercialization plan.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent